Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Unknown 2Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 2

Conditions

Thyroid Neoplasms 9Thyroid Cancer, Papillary 2Differentiated Thyroid Cancer 2Adenocarcinoma, Follicular 2Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation 1Hypothyroidism 1Heterotaxy Syndrome 1

Interventions

Thyrotropin Alfa 2vandetanib 1donafenib 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Differentiated Thyroid Cancer × Thyrotropin Alfa × Clear all
NCT04971473 2024-03-28

Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3 Completed
201 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT04137185 2024-03-06

Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1/2 Completed
64 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡